Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel

Crucell Terug naar discussie overzicht

Week 28 12 juli t/m 16 juli 2010

32 Posts
Pagina: «« 1 2 | Laatste | Omlaag ↓
  1. forum rang 9 josti5 15 juli 2010 08:04
    quote:

    Hearts23 schreef:

    Totaal onbegrijpelijke reactie maar dat zal wel aan mijn beperkte bevattingsvermogen liggen.
    Wie bedoel je met "het clubje " ?
    Mijn zwarte aangevers-lijstje ga ik natuurlijk niet met naam en toenaam op dit forum vermelden.
    Degenen die het betreft, weten het zelf maar al te goed, en aan de hand van wat combineren en deduceren is het voor iedere forumgenoot vrij eenvoudig te achterhalen, wie de monddood-makers zijn.
    Vrijheid van meningsuiting: ook in dit land voor sommigen wat meer, (en dus) voor anderen wat minder tot en met volledige liquidatie van meningsuiting.
    Een slechte zaak voor iedere serieuze Crucellwatcher: juist wat onwelgevallig overkomt houdt de belegger met beide benen op de o zo belangrijke grond.
    Het aantal facetten van 'de waarheid' is met deze ban tot onaanvaardbaar peil gedaald, althans voor een ieder, die zich serieus met dit aandeel bezighoudt.
    Schande, dat je je voor censuur laat misbruiken, IEX!
  2. forum rang 9 josti5 15 juli 2010 08:08
    quote:

    oudje schreef:

    Ach Hearts, Wim Kan zong het meer dan 30 jaar geleden al:
    NEE NEE NEE, NAMEN NOEMEN WE NIET.

    Overigens vergeet de schrijver dat wij in Nederland allemaal onze vrijheid hebben. En dat uit zich in een volkomen vrijheid van keuze van je beleggingen.
    Ron B is in ieder geval de vrijheid van meningsuiting ontnomen...

    Heel vaak zijn het juist diegenen die zo hoog opgeven over 'vrijheid', die anderen diezelfde vrijheid (willen) ontnemen: de wereldgeschiedenis staat bol van de voorbeelden, van fascist tot en met communist, en alles wat zich daartussen bevindt.
  3. flosz 15 juli 2010 10:32
    Eden Biodesign Assists Momotaro-Gene, Inc. to Commence Human Clinical Trials Less Than 12 Months After Being Engaged to Produce a Recombinant Adenovirus Vector from a New Cell Line

    Wednesday, Jul. 14, 2010
    Eden Biodesign Ltd. and Momotaro-Gene, Inc. today announced the success of a collaborative global project that demonstrated Eden’s capabilities to work quickly to develop an adenoviral manufacturing process providing Momotaro-Gene with drug substance and vialed drug product ready for their clinical trial within 12 months. Momotaro-Gene, Inc. already cleared its first IND (Investigational New Drug) application with this drug product to the FDA and expects to start its First-In-Man clinical trial at Mt. Sinai Hospital, USA, this month.
    By accessing Eden Biodesign’s expertise as a global provider of outsourced cGMP manufacturing, and through the application of Crucell’s proprietary technology, Momotaro-Gene was able to employ a PER.C6® human cell line to manufacture a recombinant adenoviral vector which is unlikely to replicate in a normal human cell line. As a result, with Eden Biodesign’s guidance, Momotaro-Gene achieved a product suitable for global regulatory approval for Phase I trials.
    Momotaro-Gene led by Prof. Hiromi Kumon at the Okayama University developed the next generation therapeutic cancer vaccine which will help treat prostate cancer patients in Japan and the United States.
    “Eden Biodesign’s involvement with Momotaro-Gene was a very fortunate alignment of knowledge, rare skills and technology,” said Dr. Crawford Brown, CEO, Eden Biodesign. “We were able to dramatically advance a project that had encountered challenges which Eden Biodesign was uniquely qualified to overcome. The team has been involved in this area for a number of years and we are excited to be working with customers in the emerging field of therapeutic vaccines and proud to contribute to product and process design.”
    “We engaged Eden Biodesign because they were previously known to us from their consultancy activities in Japan and particularly due to their ability to tackle the most-difficult biodesign challenges,” said Momotaro-Gene’s CEO, Mr. Hitoshi Shiomi. “The success of our most-recent engagement is the product of the very deliberate application of world-class talent, and we couldn’t be happier with the outcome. Eden assisted not only to supply clinical product but support our Japanese and USA regulatory approvals.”
    As well as having an established track record and engagement over the last 10 years with several Japanese companies, providing support and training to overcome technical challenges, Eden Biodesign is able to demonstrate through the work with Momotaro-Gene, Inc. that the company is much more than a CMO in providing regulatory support as part of their drug development team.

    tinyurl.com/2up3ntz
  4. maxen 15 juli 2010 11:02
    quote:

    flosz schreef:

    Eden Biodesign Assists Momotaro-Gene, Inc. to Commence Human Clinical Trials Less Than 12 Months After Being Engaged to Produce a Recombinant Adenovirus Vector from a New Cell Line
    ...
    www.crucell.com/Partners%20-%20Genera...

    Gene Therapy
    Momotaro-Gene Inc.
    Aug. 2009
    PER.C6®
    Prostate cancer
    phase I

    Dus binnen een jaar na de licentie al in phase I. Uitzonderlijk snel. De uitzondering op de regel.

  5. z0n0p 15 juli 2010 11:32
    quote:

    maxen schreef:

    [quote=flosz]
    Eden Biodesign Assists Momotaro-Gene, Inc. to Commence Human Clinical Trials Less Than 12 Months After Being Engaged to Produce a Recombinant Adenovirus Vector from a New Cell Line
    ...
    [/quote]
    www.crucell.com/Partners%20-%20Genera...

    Gene Therapy
    Momotaro-Gene Inc.
    Aug. 2009
    PER.C6®
    Prostate cancer
    phase I

    Dus binnen een jaar na de licentie al in phase I. Uitzonderlijk snel. De uitzondering op de regel.
    En meteen weer de koers pumpen!! ;)
  6. flosz 15 juli 2010 12:16
    quote:

    josti5 schreef:

    de vrijheid van meningsuiting ontnomen...
    Via een link op pagina 1 is zijn mailadres te vinden...bv om gezellig samen de Universele Verklaring van de Rechten van de mens te bespreken. ( www.ohchr.org/EN/UDHR/Documents/UDHR_... ) Maar pas op: over een jaar of twee/drie niet hier komen klagen over terreur/bedreigingen/telefonische belaging/lasterlijke leugens etc., ook niet als er serieuze pers. beveiliging aan te pas moet komen! En ach, lijstjes zijn steeds te herzien, een fin.int. syndicaatje meer of minder:BOEiend!
    "And the man with the golden gun thinks he knows so much”(T. Amos).
  7. Mr sponge 15 juli 2010 13:34
    quote:

    josti5 schreef:

    Ron B is in ieder geval de vrijheid van meningsuiting ontnomen...
    Zijn mening was niet het probleem. Maar het Spammen wel denk ik.
  8. forum rang 6 de tuinman 15 juli 2010 19:47
    quote:

    josti5 schreef:

    [quote=oudje]
    Ach Hearts, Wim Kan zong het meer dan 30 jaar geleden al:
    NEE NEE NEE, NAMEN NOEMEN WE NIET.

    Overigens vergeet de schrijver dat wij in Nederland allemaal onze vrijheid hebben. En dat uit zich in een volkomen vrijheid van keuze van je beleggingen.
    [/quote]

    Ron B is in ieder geval de vrijheid van meningsuiting ontnomen...

    Heel vaak zijn het juist diegenen die zo hoog opgeven over 'vrijheid', die anderen diezelfde vrijheid (willen) ontnemen: de wereldgeschiedenis staat bol van de voorbeelden, van fascist tot en met communist, en alles wat zich daartussen bevindt.
    En nog vaker maken personen misbruik van de diezelfde vrijheid van meningsuiting!!!!!
    De wereldgeschiedenis staat bol van de voorbeelden: de rascist, de milieuactivist, Ron B. enz enz.
    De goeden lijden altijd onder de kwaden.
  9. flosz 16 juli 2010 11:03
    …..

    OctoPlus is sindsdien klein maar solide, zeggen marktvolgers. En het sluit deals. Maandag werd een contract getekend dat 'een bijdrage van betekenis vormt aan de jaarlijkse omzet'. Het is de derde deal in amper twee weken, nadat eind juni een overeenkomst was gesloten met farmabedrijf Novartis.

    Daarmee heeft OctoPlus nog één probleem: het is te onbekend. 'If you don't have the cash flow than have the news flow', is een Engelse beurswijsheid. Dat heeft het bedrijf onvoldoende. Sinds het genoteerd is, heeft OctoPlus 83 persberichten uitgegeven. In dezelfde tijd verstuurde Galapagos 139 persberichten. Crucell verstuurde er 159.

    www.fd.nl/artikel/17398560/boven-mark...
  10. flosz 16 juli 2010 11:04
    Two-step vaccine may offer "universal" flu jab

    (The vaccine, which uses DNA from Netherlands-based Crucell NV, "looks pretty safe," Fauci said. "They are already well into, at least a full year into, a Phase 1 trial.")

    A two-step flu vaccine using DNA to "prime" the immune system and then a traditional seasonal influenza vaccine may be able to protect against all strains of the virus -- providing a long-sought "universal" flu vaccine, U.S. researchers said on Thursday.
    The team at the National Institute of Allergy and Infectious Diseases is already testing the new vaccine in people and says the results of tests in mice, ferrets and monkeys suggest the industry may finally be able to dump the cumbersome process of making fresh flu vaccines every year.
    "This is the first step, conceptually, toward a good shot at a universal vaccine," NIAID Director Dr. Anthony Fauci said in a telephone interview.
    Every year, the influenza strains that are circulating mutate a little bit and at any given time several very different strains are infecting people. In some years a new mutant pops up -- such as the new H1N1 swine flu strain that appeared in March 2009 to spark a pandemic.
    Vaccine makers have to change their formulations every year to match the current strains. To make matters worse, virtually all flu vaccines are made using decades-old technology based on chicken eggs that is both slow and prone to contamination.
    So the goal is to come up with a universal influenza vaccine that could protect people from all flu strains for decades or even for life.
    NIAID's Dr. Gary Nabel said his lab has taken a big step toward this goal. Their method, described in the journal Science, starts with a piece of DNA based on the hemagglutinin protein -- a mushroom-shaped structure on the outside of the virus that gives flu strains the "H" in their names.
    The DNA directs the body to make antibodies against a part of the flu virus that is normally hidden -- on the "stem" of the hemagglutinin protein. This part is conserved, meaning it does not change from flu strain to flu strain.
    OLD AND NEW STRAINS
    Vaccinated mice and ferrets produced antibodies that protected them against flu strains from 1934 through 2007.
    "We are excited by these results," Nabel said. "The prime-boost approach opens a new door to vaccinations for influenza that would be similar to vaccination against such diseases as hepatitis, where we vaccinate early in life and then boost immunity through occasional, additional inoculations in adulthood."
    The vaccine, which uses DNA from Netherlands-based Crucell NV, "looks pretty safe," Fauci said. "They are already well into, at least a full year into, a Phase 1 trial."
    Such trials are meant to see if a new drug or vaccine is safe in people. A larger, Phase 2 trial could start next year, Fauci said.
    Seasonal influenza kills 250,000 to 500,000 people a year globally, including 36,000 in the United States. Pandemics often kill more and while H1N1 has not been especially deadly, it has killed far more children, young adults and pregnant women than seasonal flu usually does.
    The experimental vaccine protected animals against H5N1 bird flu, as well. While avian influenza only rarely infects people, it has killed 296 of the 500 sickened by it since 2003.
    Flu experts fear H5N1 could mutate and cause a pandemic far worse than swine flu and, using current vaccine technology, it will take months to formulate a good vaccine against it. Swine flu made its spread global within six weeks. www.reuters.com/article/idUSTRE66E7BM...

    NIH Scientists Advance Universal Flu Vaccine
    www.niaid.nih.gov/news/newsreleases/2...
    www.sciencemag.org/cgi/content/abstra...
32 Posts
Pagina: «« 1 2 | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 465 6.840
AB InBev 2 5.282
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.579 46.091
ABO-Group 1 18
Acacia Pharma 9 24.692
Accell Group 151 4.129
Accentis 2 253
Accsys Technologies 22 8.870
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 160
ADMA Biologics 1 31
Adomos 1 126
AdUX 2 457
Adyen 13 16.146
Aedifica 2 828
Aegon 3.257 320.010
AFC Ajax 537 7.010
Affimed NV 2 5.736
ageas 5.843 109.775
Agfa-Gevaert 13 1.854
Ahold 3.536 73.977
Air France - KLM 1.024 34.302
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 466 12.682
Alfen 12 16.002
Allfunds Group 3 1.122
Almunda Professionals (vh Novisource) 651 4.246
Alpha Pro Tech 1 17
Alphabet Inc. 1 324
Altice 106 51.196
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.484 114.756
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.819 240.161
AMG 965 125.587
AMS 3 73
Amsterdam Commodities 303 6.512
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 382
Antonov 22.632 153.605
Aperam 91 14.104
Apollo Alternative Assets 1 17
Apple 5 313
Arcadis 251 8.613
Arcelor Mittal 2.023 318.575
Archos 1 1
Arcona Property Fund 1 266
arGEN-X 15 9.093
Aroundtown SA 1 175
Arrowhead Research 5 9.249
Ascencio 1 20
ASIT biotech 2 697
ASMI 4.107 37.534
ASML 1.762 76.476
ASR Nederland 18 4.117
ATAI Life Sciences 1 7
Atenor Group 1 322
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 29 10.626
Axsome Therapeutics 1 177
Azelis Group 1 49
Azerion 7 2.657

Macro & Bedrijfsagenda

  1. 19 april

    1. Japan inflatie maart 2,7% YoY volitaliteit verwacht
    2. WDP Q1-cijfers
    3. EU producentenprijzen maart
    4. VK detailhandelsverkopen maart
    5. Fra ondernemersvertrouwen april
    6. KPN €0,098 ex-dividend
    7. CM.com jaarvergadering
    8. NSI jaarvergadering
    9. American Express Q1-cijfers
  2. 22 april

    1. NL investeringen februari
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht